A Phase 1 interventional study of Extended-release Bupropion Hydrochloride in Depressive Disorder, sponsored by GlaxoSmithKline. Completed at 48 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-09-25.
Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Seasonal Affective Disorder with a site in United States — none open to participants now, none under way, none of them phase 3. Seasonal Affective Disorder · United States.
Among the 18 studies in Seasonal Affective Disorder with a site in United States, this one is the 2nd largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2003, is one of 2 in phase 1, and was the 6th registered.
31 studies on the registry are indexed under Seasonal Affective Disorder; 2 are open to participants now.
Browse Seasonal Affective Disorder studies →None of the 18 studies in Seasonal Affective Disorder with a site in United States is open now. The open studies under Seasonal Affective Disorder, anywhere →
Of the 1 Seasonal Affective Disorder study recruiting now, 1 sets no upper age limit and none stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 3 · Phase 4 1
First in 1995; this study’s year is marked. 1 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 250 is above the median of 60 across 25 interventional studies indexed under Seasonal Affective Disorder.
Median enrollment 61 across the 15 interventional studies, 73 across the 2 observational. Of the 16 that completed or were terminated, 6 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 18 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
GlaxoSmithKline has 3 studies filed under Seasonal Affective Disorder — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 18 studies in Seasonal Affective Disorder with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A placebo controlled study evaluating the effectiveness of medication in preventing winter depressive episodes in patients with a history of Seasonal Affective Disorder
A 7-Month Multicenter, Parallel, Double-Blind, Placebo-Controlled Comparison of 150-300mg/day of Extended-release Bupropion Hydrochloride and Placebo for the Prevention of Seasonal Depressive Episodes in Subjects with a History of Seasonal Affective Disorder Followed by an 8-week Observational Follow-up Phase
31 studies on the registry are indexed under Seasonal Affective Disorder; 2 are open to participants now.
This study's enrollment of 250 is above the median of 60 across 25 interventional studies indexed under Seasonal Affective Disorder.
Browse Seasonal Affective Disorder studies →GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
Compared within Seasonal Affective Disorder, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Depressive Disorder. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Extended-release Bupropion Hydrochloride
Drug: Extended-release Bupropion Hydrochloride
Bupropion hydrochloride will be available in dose strength of 150 and 300 milligram (mg). Subjects will receive one tablet of 150 mg bupropion hydrochloride from Day 1 to 7, from Day 8 to Week 27 will receive one tablet of 300 mg bupropion hydrochloride and from Week 28-29 one tablet of bupropion hydrochloride
End of season depression-free rate.
Time frame: 7 months
Time to onset of a seasonal depressive episode.Change from randomization on SIGH-SAD and HAMD-17.
Time frame: 7 months
Ran from Sep 2003 to primary completion in Jun 2004, 8 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bupropion